Vericel Co. (NASDAQ:VCEL) Director Steven C. Gilman Sells 5,833 Shares

Vericel Co. (NASDAQ:VCEL) Director Steven C. Gilman sold 5,833 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total transaction of $235,361.55. Following the transaction, the director now directly owns 11,000 shares of the company’s stock, valued at $443,850. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Vericel Price Performance

NASDAQ:VCEL opened at $43.36 on Friday. The firm has a 50-day moving average of $46.57 and a two-hundred day moving average of $47.30. The stock has a market cap of $2.11 billion, a P/E ratio of -4,336.00 and a beta of 1.67. Vericel Co. has a 1-year low of $30.18 and a 1-year high of $54.10.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). Vericel had a return on equity of 0.35% and a net margin of 0.37%. The firm had revenue of $52.70 million during the quarter, compared to the consensus estimate of $52.59 million. During the same quarter in the prior year, the business posted ($0.11) earnings per share. Vericel’s revenue for the quarter was up 14.8% on a year-over-year basis. As a group, equities analysts expect that Vericel Co. will post 0.12 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Canaccord Genuity Group started coverage on Vericel in a research report on Friday, August 9th. They issued a “buy” rating and a $57.00 target price on the stock. TD Cowen raised their price target on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, August 27th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Monday, September 30th. Stephens raised their target price on shares of Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Canaccord Genuity Group started coverage on shares of Vericel in a research report on Friday, August 9th. They set a “buy” rating and a $57.00 price target for the company. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $55.75.

Institutional Trading of Vericel

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. MCF Advisors LLC grew its holdings in Vericel by 86.1% during the 1st quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 223 shares in the last quarter. CWM LLC grew its stake in Vericel by 319.0% in the second quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 504 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in Vericel by 9.7% in the second quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 220 shares during the last quarter. Lazard Asset Management LLC raised its stake in Vericel by 178.7% during the first quarter. Lazard Asset Management LLC now owns 2,584 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 1,657 shares in the last quarter. Finally, RiverPark Advisors LLC bought a new position in Vericel during the 1st quarter worth approximately $147,000.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.